NCT03673826 - Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 19, 2018

Primary Completion Date

August 31, 2024

Study Completion Date

December 31, 2028

Conditions

Smouldering Myeloma

Interventions

DRUG

Carfilzomib

9 cycles 20/36mg/m2 days 1,2,8,9,15,16

DRUG

Dexamethasone

4 cycles 20 mg days 1,2,8,9,15,16,22,23 followed by 5 cycles 10mg days 1,2,8,9,15,16,22,23

DRUG

Lenalidomide

9 cycles 25mg days 1-21 followed by 24 extended dosing cycles 10mg days 1-21

Trial Locations (16)

CZ-Brno-UHBRNO, Brno

CZ-Ostrava-Poruba-FNO, Ostrava

IT-Ancona-UMBERTOA, Ancona

IT-Bologna-MALPHIGI, Bologna

IT-Brescia-SPEDALICIVILI, Brescia

IT-Roma-SAPIENZA, Roma

IT-Torino-MOLINETTE, Torino

NL-Den Bosch-JBZ, 's-Hertogenbosch

NL-Amsterdam-VUMC, Amsterdam

NL-Hoofddorp-SPAARNEGASTHUIS, Hoofddorp

NL-Leeuwarden-MCL, Leeuwarden

NL-Nijmegen-RADBOUDUMC, Nijmegen

NL-Rotterdam-ERASMUSMC, Rotterdam

NL-Sittard-Geleen-ZUYDERLAND, Sittard

NL-Utrecht-UMCUTRECHT, Utrecht

NO-Oslo-OSLOUH, Oslo

All Listed Sponsors

lead

Stichting Hemato-Oncologie voor Volwassenen Nederland

OTHER